Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29896119 | 1.00 | ABL1 (0.40) | ABL1ROCK2ROCK1HPGDSRIPK1 | |
| SCHEMBL29896087 | 0.86 | ROCK2 (0.47) | ABL1ROCK2ROCK1EPHX2 | |
| SCHEMBL23143269 | 0.86 | ROCK2 (0.47) | ABL1ROCK2ROCK1EPHX2 | |
| SCHEMBL29766199 | 0.85 | HPGDS (0.39) | ROCK2ROCK1HPGDSEPHX2POLB | |
| SCHEMBL27188858 | 0.85 | HPGDS (0.39) | ABL1ROCK2ROCK1HPGDSEPHX2 | |
| SCHEMBL23143262 | 0.85 | HPGDS (0.39) | ROCK2ROCK1HPGDSEPHX2POLB | |
| SCHEMBL29896158 | 0.84 | POLB (0.47) | ROCK2ROCK1RIPK1EPHX2DGAT2 | |
| SCHEMBL27188891 | 0.84 | POLB (0.47) | ROCK2ROCK1RIPK1EPHX2DGAT2 | |
| SCHEMBL27188861 | 0.82 | ALDH1A1 (0.40) | ROCK2ROCK1HPGDSPOLB | |
| SCHEMBL29896165 | 0.82 | ROCK2 (0.44) | ROCK2ROCK1RIPK1EPHX2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | claimed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885ROCK2 4595/4885ROCK1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.